Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Enlivex Therapeutics is an Israeli clinical-stage immunotherapy company focused on developing Allocetra, a universal, off-the-shelf cell therapy. Allocetra is designed to reprogram macrophages into their homeostatic state, aiming to treat life-threatening or debilitating diseases such as sepsis and osteoarthritis, which involve acute or chronic inflammation not resolvable by existing therapeutics. The company's therapy has shown potential in treating severe cases of conditions like sepsis and complications arising from viral infections, including COVID-19, by rebalancing the immune system. [2, 5, 7]
Portfolio
No portfolio companies in this dataset yet.
Investment activity
1 portfolio exit on record.
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is Shai Novik's primary investment focus by sector?
- Shai Novik primarily focuses on the Health Tech & Life Sciences sector, with all recorded portfolio companies and exits falling within this area.
- Can you name a notable exit for Shai Novik?
- In March 2019, Shai Novik had an exit with Enlivex Therapeutics via a Reverse Merger Event, which subsequently listed on NASDAQ.
- Which company is a key part of Shai Novik's portfolio?
- A key company in Shai Novik's portfolio is Enlivex Therapeutics, which develops macrophage reprogramming cell therapies for life-threatening diseases and has raised $286.9M.
- When did Shai Novik make their most recent recorded investment?
- Shai Novik's most recent recorded investment activity was in May 2014.
- What type of funding stage has Shai Novik participated in?
- Shai Novik has participated in Debt Financing rounds.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2009 |
|---|
Radar intelligence
Patents
| EPO | 12 |
|---|